Silexion Therapeutics reports financial results for 2024, focusing on progress in RNAi therapies.

From GlobeNewswire: 2025-03-18 16:29:00

Silexion Therapeutics Corp. reported financial results for Q4 and full year 2024, highlighting progress in RNAi therapies for KRAS-driven cancers. Recent achievements include the completion of a merger, progress in clinical programs, and advancements for SIL204. Financially, the company raised $3.1 million through an Equity Line of Credit and an additional $9.1 million through a priced offering and warrant exercises. Operating expenses for 2024 were $12.6 million, with a net loss of $16.5 million. Silexion aims to initiate Phase 2/3 clinical trials for SIL204 by the first half of 2026, targeting locally advanced pancreatic cancer.

Silexion Therapeutics Corp. provided a corporate update, reporting a cash position of $1.2 million as of December 31, 2024. The company made significant progress in preclinical studies for SIL204, demonstrating its potential in reducing tumor growth and metastatic spread. With a focus on advancing therapeutic innovation in oncology, Silexion remains committed to improving outcomes for patients with difficult-to-treat cancers. Financially, total operating expenses for 2024 were $12.6 million, leading to a net loss of $16.5 million. Silexion is preparing for Phase 2/3 clinical trials for SIL204 by the first half of 2026.



Read more at GlobeNewswire: Silexion Therapeutics Reports Full Year 2024 Financial